Skip to main content
. Author manuscript; available in PMC: 2020 Jan 10.
Published in final edited form as: Nat Rev Cancer. 2019 Apr;19(4):197–214. doi: 10.1038/s41568-019-0123-y

Table 2.

Therapeutic targets of inflammasomes in cancer

Therapy Inflammasome
Target		 Cancer type Clinical trial Phase
Anakinra IL-1β Metastatic breast cancer Phase I/NCT01802970 203
Anakinra IL-1β Metastatic CRC PhaseII/NCT02090101173
Anakinra IL-1β Multiple myeloma Plasma cell neoplasm PhaseII/NCT00635154168,169
Canakinumab/Ilaris IL-1β CRC, breast cancer, NSCLC, adenocarcinoma Phase I/NCT02900664
Thalidomide Caspase-1 Multiple myeloma204,205 N/A
MCC950/CRID3 NLRP3 Head and neck SCC206 N/A
Glyburide NLRP3207 N/A N/A
BOT-4-one NLRP3 Lymphoma167 N/A
IL-18BP IL-1890 N/A
Methylene blue NLRP3, AIM2, NLRC4208 N/A N/A
CY-09 NLRP3209 N/A N/A

Abbreviations: CRC, colorectal cancer; IL-18BP, IL-18–binding protein, N/A, information not available; NSCLC, non–small cell lung cancer; SCC, squamous cell carcinoma.